Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
May 10 (Reuters) - Britain's FTSE 100 rose on Tuesday, boosted by financials and healthcare stocks, a day after worries around recession risks, higher interest rates, and extended COVID-19 lockdowns in China triggered a bruising sell-off on the blue-chip index.
Read moreMay 9 (Reuters) - COVID-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months.
Read moreMay 6 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.
Read more
(Alliance News) - AstraZeneca PLC on Thursday reported several positive developments in its pipeline, including its breast cancer drug clearing another regulatory hurdle, and positive phase III trial results for Farxiga and Ultomiris.
Read more
(Sharecast News) - AstraZeneca said its treatment for an autoimmune disease that attacks the central nervous system had met a primary endpoint in a phase 3 trial.
Read moreMay 4 (Reuters) - UK's benchmark equities index declined on Wednesday, weighed by weakness in consumer staple and healthcare shares, while investors awaited the Federal Reserve's interest rate decision later in the day.
Read more(Alliance News) - AstraZeneca PLC on Wednesday said its checkpoint inhibitor drug Imfinzi, generically durvalumab, has been granted priority review by the US Food & Drug Administration.
Read more(Alliance News) - JD Wetherspoon on Wednesday said sales improved steadily since the ending of all Covid restrictions, but the pub chain said virus woes have been replaced by "considerable pressure on costs" as a new source of concern.
Read more(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that a supplemental biologics license application for its Imfinzi asset, in combination with standard-of-care chemotherapy, had been accepted and granted priority review in the US for patients with locally advanced or metastatic biliary tract cancer.
Read more(Alliance News) - Stocks in London on Friday ended a volatile month of April in a positive fashion, amid a continued rush of company earnings, while markets in the US sank as high-profile tech names disappointed.
Read moreApril 29 (Reuters) - London's FTSE 100 rose on Friday, driven by miners and strong quarterly earnings, with investors now focused on the Bank of England meeting next week amid concerns over the soaring cost of living.
Read moreApril 29 (Reuters) - AstraZeneca's COVID-19 vaccine still has a role to play in the fight against the pandemic, even as sales slow and the company charges more in some places, CEO Pascal Soriot said on Friday, the latest drugmaker to warn about a global supply glut.
Read more(Alliance News) - AstraZeneca PLC on Friday reported a sharp rise in first-quarter revenue, though profit declined, and the drugmaker also announced plans for a new strategic site in the US.
Read moreApril 29 (Reuters) - AstraZeneca's COVID-19 vaccine still has market potential despite an expected global oversupply of shots and delays in the vaccine's approval in the United States, its chief executive Pascal Soriot said on Friday.
Read more(Sharecast News) - AstraZeneca said on Friday that its total revenue for the first quarter surged 60% to $11.39bn (£9.07bn), with growth across the company seeing it reiterate its full-year guidance.
Read more
Last checked at